MENS
Jyong Biotech Ltd.
Set alert
1.88 USD 0.00 0.00%
1.84 Day range 1.96
1.46 52-week range 45.01
- YTD
- -52.41%
- 1 year
- -95.82%
- Open
- 1.91
- Prev close
- 1.88
- Mkt cap
- 142.93M
- Vol
- 18.78K
- Avg vol
- 42.86K
- EPS
- -0.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.84
- High
- 1.96
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.56
- Inst. own
- 0.14%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 40.49
- 200-d avg
- 36.26
- 1y target
- 0.00
Key statistics
- Market cap
- 222.00M
- Enterprise value
- 1.16B
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.04
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -1.73M
- Total cash
- 98.00K
- Total debt
- 18.14M
- Return on equity
- 0.00%
- Shares outstanding
- 76.03M
- Short % of float
- 0.45%
- 50-day average
- 40.49
- 200-day average
- 36.26
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
MENS Revenue — quarterly 47.68M
MENS Net income — quarterly 2.69M
MENS EPS — quarterly 0.26
About Jyong Biotech Ltd.
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Taiwan
- Website
- jyongbio.com
News
- Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California
- Jyong Biotech Plans Potential Texas Manufacturing Facility And U.S. Operations Center To Support Future Commercialization Of Drug Candidates
- Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
- Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
- Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
- Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
- Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
- Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages
Your note
Sign in to keep a note on MENS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.07% | 53,844 | 157.22K | Sep 29, 2025 |
| HRT Financial LP | 0.03% | 20,819 | 60.79K | Sep 29, 2025 |
| Millennium Management Llc | 0.02% | 13,013 | 38.00K | Sep 29, 2025 |
| Citadel Advisors Llc | 0.02% | 12,641 | 36.91K | Sep 29, 2025 |
| BNP Paribas Financial Markets | 0.00% | 1,698 | 4.96K | Sep 29, 2025 |
| UBS Group AG | 0.00% | 537 | 1.57K | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.05% | 35,802 | 104.54K | Sep 29, 2025 |
| Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF | 0.02% | 18,042 | 52.68K | Sep 29, 2025 |